WDB coco Co., Ltd. (TYO:7079)
2,705.00
-4.00 (-0.15%)
At close: Feb 13, 2026
WDB coco Revenue
WDB coco had revenue of 1.22B JPY in the quarter ending December 31, 2025, a decrease of -12.18%. This brings the company's revenue in the last twelve months to 4.98B, down -4.55% year-over-year. In the fiscal year ending March 31, 2025, WDB coco had annual revenue of 5.33B with 15.91% growth.
Revenue (ttm)
4.98B
Revenue Growth
-4.55%
P/S Ratio
1.31
Revenue / Employee
8.79M
Employees
566
Market Cap
6.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.33B | 731.00M | 15.91% |
| Mar 31, 2024 | 4.60B | 525.00M | 12.90% |
| Mar 31, 2023 | 4.07B | 455.00M | 12.59% |
| Mar 31, 2022 | 3.62B | 1.05B | 40.66% |
| Mar 31, 2021 | 2.57B | 285.00M | 12.47% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 66.38B |
| Fuso Pharmaceutical Industries,Ltd. | 62.05B |
| Nippon Chemiphar | 32.52B |
| Morishita Jintan | 12.90B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 5.94B |
| SymBio Pharmaceuticals | 1.31B |
| Solasia Pharma K.K. | 326.00M |